ANDRÉS
DE LAROCHA MUÑOZ
Novartis (Sweden)
Täby, SueciaNovartis (Sweden)-ko ikertzaileekin lankidetzan egindako argitalpenak (1)
2023
-
Ligelizumab impairs IgE-binding to plasmacytoid dendritic cells more potently than omalizumab and restores IFN-α production and FOXP3+ Treg generation
Allergy: European Journal of Allergy and Clinical Immunology, Vol. 78, Núm. 4, pp. 1060-1072